EUCTR2010-020424-21-NL
进行中（未招募）
不适用
Betablocker Therapy in Pulmonary Arterial Hypertension
VU medical center0 个研究点2010年8月30日
概览
- 阶段
- 不适用
- 干预措施
- 未指定
- 疾病 / 适应症
- 未指定
- 发起方
- VU medical center
- 状态
- 进行中（未招募）
- 最后更新
- 14年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •Population:
- •The VUMC serves as a national tertiary referral centre for the diagnosis and treatment of PAH and had 1500 referrals in 10 years. Currently more than 100 idiopathic PAH patients are treated in the VUMC, which make it possible to select our study population with care from this large cohort.
- •We choose to limit our study to idiopathic PAH patients, since this is a well\-characterized homogenous group with little or no co\-morbidities. It is estimated that the current prevalence of iPAH in the Netherlands is about 200 patients. However, if our results turn out to be positive this might have an important impact on the management of other more common types of pulmonary hypertension.
- •Inclusion criteria
- •From our database containing currently 156 PAH patients we will carefully select patients who meet the following inclusion criteria:
- •Idiopathic PAH patients
- •Stable on PAH specific treatment defined
- •oNo change in PAH specific treatment in the past 6 months
- •oNo change in functional class in the past 6 months
- •o\<10 % change in 6 minute walk distance in the past 6 months
排除标准
- •Exclusion criteria are
- •History of systemic hypertension, ischaemic heart disease, valvular disease or cardiomyopathy.
- •Use of concomitant medication other than diuretics, Acenocoumarol and PAH targeted therapy
- •History of cardiac arrhythmias or the use of anti\-arrhythmic drugs
- •Sick sinus syndrome
- •systolic hypotension \< 90 mmHg
- •Clinically relevant sinus\-bradycardia.
结局指标
主要结局
未指定
相似试验
已完成
2 期
Betablocker Therapy in Pulmonary Arterial Hypertensioidiopathische pulmonale hypertensiehigh bloodpressure pulmonary vascular systempulmonary hypertension10019280NL-OMON34177Vrije Universiteit Medisch Centrum30
进行中（未招募）
1 期
Racecadotril used in combination with sildenafil to reduce blood pressure in the lungs.Pulmonary hypertensionMedDRA version: 14.1 Level: PT Classification code 10037400 Term: Pulmonary hypertension System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2012-003921-13-GBniversity College London21
招募中
2 期
Bosentan and Sildenafil in Pulmonary Hypertension in Cardiac AnesthesiaPACTR202209903019732Mansoura university40
终止
1 期
Carvedilol PAH A Pilot Study of Efficacy and SafetyPulmonary HypertensionCardiac MRI <40NCT02120339University of Minnesota5
终止
2 期
Beta-blockers in Pulmonary Arterial HypertensionPulmonary Arterial HypertensionNCT02507011University of Minnesota2